We calculated the incremental cost of the educational video intervention versus treatment as usual from a National Health Service (NHS) perspective. We applied unit costs from market prices and published sources [5]. Our main analysis is based on an HA (Band 7) conducting three tests Anticancer Compound Library manufacturer per hour. In sensitivity analyses we explored the impact of using different staff and increasing the number of tests per hour. Full details of the methodology

used and results have been previously published [6]. During the pilot period there were 606 eligible admissions to the AAU. Three-quarters (456 of 606; 75.3%) of all eligible admissions were approached to participate in the study. There were no significant differences in gender, age, ethnicity, presence of HIV indicator condition [1] or length of stay between those approached and not approached. Despite often multiple attempts, over half (53.5%) of approaches failed as patients were frequently absent or too unwell. Of the 282 patients who were asked if they would be involved in Selleckchem Carfilzomib the pilot project, 153 (54.3%) agreed. On introduction of the video, four patients asked to have an HIV test but did not want to watch the video, and five disclosed that they had recently been tested for HIV and therefore withdrew from further involvement. After watching the video, a further 11 patients declined to be tested: four had been tested within

the past 3 months; two had never been sexually active; two declined because of communication difficulties; one wanted to be tested in an anonymous environment and was referred to a sexual health clinic; one became unwell during the video; and one declined. In all, of the 140 patients who watched the video and had not been tested for HIV in the preceding 3 months, 93.6% (131 of 140) agreed

to a test. All patients received their results at the time of testing. There was no difference in uptake of the video or HIV test by gender, or in uptake of the Grape seed extract test by age. In total, 23.0% of eligible admissions during the pilot period had a POCT, and 25.7% left the AAU knowing their HIV status, having been tested on that admission or within the preceding 3 months or having previously been diagnosed HIV positive. Three tests (2.2%; three of 135) were reactive on POCT and all were confirmed HIV positive on further laboratory testing. All three patients were seen by specialist HIV services while in-patients and remained engaged with HIV services 12 months on. Only one of the three had previously been tested for HIV, over 5 years previously. The majority of participants who completed the survey were male (58.6%), with a median age of 38.5 years. Over half (51.9%) resided in the hospital catchment area and 85.5% were from within London. In total, 42.8% were born abroad: 19 (12.5%) in Europe, 17 (11.2%) in Africa [nine (5.9%) black African] and 15 (9.9%) in Asia or the Indian subcontinent. Forty per cent (61 of 152) of participants had previously been tested for HIV; however, only 22 (14.